<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05049668</url>
  </required_header>
  <id_info>
    <org_study_id>EBMT-RACE 2</org_study_id>
    <nct_id>NCT05049668</nct_id>
  </id_info>
  <brief_title>RACE 2: a Long Term Follow-up of Patients Participating in the RACE Trial</brief_title>
  <acronym>RACE2</acronym>
  <official_title>Long-term Follow-up of Patients Participating in RACE: the Prospective Randomized Multicenter Study Comparing Horse Antithymocyte Globuline (hATG) + Cyclosporine A (CsA) With or Without Eltrombopag as Front-line Therapy for Severe Aplastic Anemia Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Society for Blood and Marrow Transplantation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Society for Blood and Marrow Transplantation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      After exiting the RACE trial (NCT02099747) patients will be invited to participate in this&#xD;
      long term follow-up study&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be followed up annually, according to standard of care.&#xD;
&#xD;
      All diagnostic and therapeutic intervention will be performed according to standard of care,&#xD;
      at discretion of the treating physician. In particular, during the study no extra Peripheral&#xD;
      blood or Bone Marrow sampling will be performed, in addition to routine sampling for&#xD;
      morphology and karyotype surveillance.&#xD;
&#xD;
      Molecular analysis by Next Generation Sequencing (NGS) will also be collected if the centre&#xD;
      is doing this on a routine basis.&#xD;
&#xD;
      No Investigational Medicinal Product (IMP) or Non-Investigational Medicinal Product (NIMP)&#xD;
      will be given to the patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">December 2034</completion_date>
  <primary_completion_date type="Anticipated">December 2033</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>15 Years</target_duration>
  <primary_outcome>
    <measure>Failure Free Survival</measure>
    <time_frame>15 years</time_frame>
    <description>Failure Free Survival, where treatment failure is defined as one or more of the following: death, relapse, malignant clonal evolution, need for further (e.g. transplant)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response Rate: number of patients who reach a hematological response</measure>
    <time_frame>15 years</time_frame>
    <description>Response Rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>15 years</time_frame>
    <description>Overall Survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of relapse after response</measure>
    <time_frame>15 years</time_frame>
    <description>Cumulative incidence of relapse after initial hematological response (complete or partial)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of clonal evolution</measure>
    <time_frame>15 years</time_frame>
    <description>Cumulative incidence of clonal evolution: Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) or karyotypic abnormalities qualifying for the diagnosis of MDS (see World Health Organization (WHO) 2016)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of clinical Paroxysmal nocturnal hemoglobinuria (PNH)</measure>
    <time_frame>15 years</time_frame>
    <description>Cumulative incidence of clinical PNH (hemolysis and/or thromboembolism), and of need of anti-complement treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of Solid Tumors</measure>
    <time_frame>15 years</time_frame>
    <description>Cumulative incidence of solid tumours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients who need a Human Stem Cell Transplantation (HSCT)</measure>
    <time_frame>15 years</time_frame>
    <description>Need for HSCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients who need additional IST</measure>
    <time_frame>15 years</time_frame>
    <description>Need for additional intensive Imune Suppressive Therapy (IST) (e.g. ATG, alemtuzumab or cyclophosphamide-based, or any other lymphocyte-depleting agent)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients who need Maintenance IST (e.g. CsA beyond 2 years)</measure>
    <time_frame>15 years</time_frame>
    <description>Need for maintenance intensive IST (e.g. CsA beyond 2 years)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients who need additional Eltrombopag (EPAG)</measure>
    <time_frame>15 years</time_frame>
    <description>Need for additional EPAG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients who need any other approved Aplastic Anemia (AA) treatment</measure>
    <time_frame>15 years</time_frame>
    <description>Need for any other approved Aplastic Anemia (AA) treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monitoring of Clonal Hematopoiesis of Indetermined Potential (CHIP)</measure>
    <time_frame>15 years</time_frame>
    <description>As tracked by somatic mutations in genes associated with myeloid disorders</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">197</enrollment>
  <condition>Severe Aplastic Anemia</condition>
  <arm_group>
    <arm_group_label>RACE 1 patients</arm_group_label>
    <description>After exiting the RACE trial (NCT02099747) patient will be invited to participate in this study</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATGAM plus CsA with or without Eltrombopag</intervention_name>
    <description>Standard treatment with or without Eltrombopag</description>
    <arm_group_label>RACE 1 patients</arm_group_label>
    <other_name>hATG+CsA +/- Revolade</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who participated in the initial RACE 1 trial&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject participated in the RACE trial (NCT02099747, EudraCT number: 2014-000363-40)&#xD;
             during which patient received ATGAM, Cyclosporine A with or without Eltrombopag.&#xD;
&#xD;
          2. Subject has provided informed consent to participate in long-term data collection&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        None&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Regis Peffault de Latour, Prof, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital St. Louis, Paris, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antonio M Risitano, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Avellino, Napels, Italy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital St. Louis</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 13, 2021</study_first_submitted>
  <study_first_submitted_qc>September 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 20, 2021</study_first_posted>
  <last_update_submitted>September 21, 2021</last_update_submitted>
  <last_update_submitted_qc>September 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Aplastic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

